DUP 697

Drug Profile

DUP 697

Latest Information Update: 07 Aug 1995

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Otsuka Pharmaceutical
  • Developer Otsuka Pharmaceutical
  • Class Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 07 Aug 1995 Discontinued-I for Rheumatoid arthritis in Japan (Unknown route)
  • 07 Aug 1995 Discontinued-I for Osteoarthritis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top